BPS BPS-Pharmacotherapy Actual Free Exam Questions & Community Discussion

A 50-year-old patient presents to the physician complaining of anxiety, insomnia, a depressed mood, and decreased energy level. Paroxetine therapy is initiated. Which symptom will be the last to respond?

A patient presents at a physician's office with gait unsteadiness and clumsiness. The patient has a history of type 2 diabetes mellitus, hypertension, and chronic numbness and tingling of the feet and fingertips.
Examination reveals mild distal wasting, glove-and-stocking sensory impairment, absent ankle jerks, brisk knee jerks, and bilateral Babinski reflexes. Gait is slightly ataxic.
CBC reveals a hemoglobin of 10.1 g/dL, WBC of 4,500 cells/mL, MCV 120 fL, and platelets
163,000 cells/ul.
Which of the following is the most important laboratory test for assisting in diagnosis?

A 65-year-old man presents to the internal medicine clinic with decreased exercise tolerance, lower extremity edema, and shortness of breath.
He has a history of diastolic dysfunction (ejection fraction of 60%) and hypertension; BP =
150/90 mm Hg, HR = 86 bpm.
Current medications include digoxin 125 mcg daily, furosemide 40 mg daily, enalapril 10 mg twice daily, aspirin 325 mg daily, and potassium 10 mEq twice daily. The digoxin concentration is 0.4 ng/mL.
After resolution of this exacerbation, which of the following should the pharmacotherapy specialist recommend to the internist regarding this patient's maintenance drug therapy?

A hospital requests a policy and procedure document for the monitoring and reporting of significant adverse drug reactions. Which agency requires a policy for the reporting of adverse drug reactions by hospitals?

In order to assess the effect of a potential metabolic enzyme inhibitor on the clearance of warfarin, the most appropriate study design would be which of the following?

A study shows that the participants who received 6 months of a new oral anticoagulant after a venous thromboembolism were randomized to continue with the new oral anticoagulant (n =
612) or to placebo (n = 611) for 18 months. Thromboembolism recurred in 12 subjects in the new oral anticoagulant group and 71 subjects in the placebo group (hazard ratio 0.17; 95% CI, 0.09-
0.30; p < 0.001).
Which of the following statements regarding these results is correct?

The Randomized Aldactone Evaluation Study (RALES) yielded the following results:
* Placebo death rate: 386/841
* Spironolactone death rate: 284/822
Given these data, which of the following is the relative risk reduction for death with spironolactone, in comparison with placebo?

After the first intravenous bolus dose of a drug, the peak concentration is 50 mcg/mL, the elimination rate constant is 0.3/h, and the dosage Interval is 6 hours. Assuming a one compartment model and intravenous bolus injection, which of the following will be the peak concentration following the second dose?

With regard to the privacy rule of the Health Insurance Portability and Accountability Act (HIPAA), which of the following statements is correct with regard to the use or disclosure of Protected Health Information (PHI) in clinical research?

The Joint Commission requires accredited organizations to encourage which groups to report concerns about safety?